Inactive Instrument

Press Releases Immunoprecise Antibodies Ltd Toronto S.E.

Equities

TQY

CA87588T2020

Press Releases

Unlock all the news: Be the first to know and act before the market!

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024	Jul. 15	BU
ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer	Jun. 27	BU
IPA's Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai	Jun. 26	AQ
IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™	Jun. 25	BU
ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai Technology	Jun. 13	AQ
ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology	Jun. 12	BU
BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery	Jun. 10	BU
IPA's Subsidiary, BioStrand, Announces Advanced Large Language Model for Electronic Health Records	Jun. 05	AQ
IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)	Jun. 04	BU
InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications	Mar. 28	BU
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments	Mar. 20	BU
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024	Mar. 15	AQ
ImmunoPrecise Antibodies : Q3 2024 Earnings Presentation	Mar. 14	PU
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*	Mar. 14	BU
IMMUNOPRECISE ANTIBODIES : MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2024 - Form 6-K	Mar. 14	PU
ImmunoPrecise Antibodies : Q3 2024 Earnings Transcript	Mar. 13	PU
IPA's subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology	Mar. 08	AQ
IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology	Mar. 07	BU
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024	Mar. 04	BU
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024	Dec. 15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Immunoprecise Antibodies Ltd Toronto S.E.

Equities

TQY

CA87588T2020

Press Releases

Filters